Last updated on November 2018

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease


Brief description of study

The proposed study will be a 24-week, randomized, double-blind, multi-site, placebo-controlled study in volunteers with late mild cognitive impairment (MCI) or early dementia due to Alzheimer's disease (AD).

Detailed Study Description

The study is a 24-week, randomized, double-blind, multi-site, placebo-controlled study in volunteers with late mild cognitive impairment (MCI) or early dementia due to Alzheimer's disease (AD). The study is designed to evaluate the safety, tolerability, drug target engagement and neurobiological effects of treatment with AMX0035 over 24 weeks. The study is designed to yield deep phenotyping insight for the purposes of demonstrating the effects of AMX0035 on mechanistic targets of engagement and disease biology. The study will evaluate diverse disease-relevant markers and produce an informative dataset that will allow for evaluation and correlation of imaging-based markers, neurobiological changes, functional measures, and cognitive outcomes.

Clinical Study Identifier: NCT03533257

Contact Investigators or Research Sites near you

Start Over

Judy Phillips

Rush University Medical Center
Chicago, IL United States
  Connect »

Alison J McManus, DNP

Massachusetts General Hospital
Boston, MA United States
  Connect »

Lauren Fedor

Rowan University
Stratford, NJ United States
  Connect »

Ruth Tejeda

Columbia University
New York, NY United States
  Connect »

Laura Schankel

Penn Memory Center
Philadelphia, PA United States
  Connect »

KUMC Recruitment Division

University of Kansas Clinical Research Center
Fairway, KS United States
  Connect »

Caroline Meuser

Mount Sinai Alzheimer's Disease Research Center
New York, NY United States
  Connect »